" class="no-js "lang="en-US"> MedRhythms Study Shows Positive Results in Parkinson's Disease
Friday, June 14, 2024

MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease

MedRhythms announced the successful completion of a multi-site feasibility study of MR-005, its investigational asset in development for the treatment of gait deficits in Parkinson’s disease (PD).

The MR-005 feasibility study results revealed enhanced quality of life and high patient adherence rates, which were the primary endpoints for this study. Additionally, preliminary results showed improvement in motor symptoms of Parkinson’s disease, walking capacity and functional mobility, only a couple weeks after MedRhythms announced positive topline results from a pivotal trial of MR-001, in development for gait deficits in chronic stroke.

“As MedRhythms works to create a world where everyone with neurologic injury and disease has access to the highest quality care, it’s essential that we make progress on the research and development of our pipeline across a range of neurological conditions,” said Brian Harris, CEO and Co-Founder of MedRhythms. “In successfully completing our first clinical trial in Parkinson’s disease in collaboration with Boston University and one of the world’s leading hospitals, we have made significant progress on the advancement of our pipeline. The clinical feasibility from this trial and our recently completed pivotal trial in chronic stroke is essential as we work toward our goal of building next-generation neurotherapeutics that are evidence-based and can positively impact the lives of patients around the world.”

The research study was conducted as an Investigator-Initiated Trial. Dr. Terry Ellis, Associate Professor and Chair of the Department of Physical Therapy at the Boston University College of Health & Rehabilitation Sciences: Sargent College, was one of the Principal Investigators.

“The results from this study related to adherence and early signals of clinical improvements with Parkinson’s disease patients are compelling and suggest that this could be a promising intervention for improving gait deficits in this population,” said Dr. Terry Ellis. “I look forward to conducting further research to investigate the impact of this intervention on people who are diagnosed with Parkinson’s disease.”

The results of this study will be submitted for a peer-reviewed publication and also presented at the upcoming American Physical Therapy Association Combined Sections Meeting. Based on these encouraging results a follow-on clinical study with MR-005 in adults with Parkinson’s disease is now underway.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more